I'm Anish Rai, founder of Nivesh Research, based in Indore, Madhya Pradesh. I bring over 14 years of experience in the securities and financial markets.
Trade Ideas
157
Opinions
283
Followers
2k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%
Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 3 hours ago
IT Stocks Surge Up to 4%: TCS, Infosys, Persistent Systems
IT Stocks Surge Up to 4%: TCS, INFY , Persistent Systems and HCLTech Lead Gains Amid Global AI Weakness
Synopsis
Indian IT shares witnessed strong buying momentum on Friday, with TCS, Infosys, Persistent Systems and HCLTech advancing up to 4%, despite a broader sell-off in global AI-related stocks.
The gains came after Anthropic made an impressive stock market debut, listing nearly 34% above its issue price. However, concerns surrounding AI-led disruption and elevated valuations continued to pressure several global technology stocks.
Meanwhile, Jefferies pointed to improving growth prospects for the Indian IT sector, although the recovery remains uneven. Investors are closely tracking global demand, AI-driven opportunities and the potential impact of emerging technologies on traditional IT services.
#TCS #Infosys #PersistentSystems #HCLTech #IndianITSector #Anthropic #ArtificialIntelligence #AIStocks #StockMarketNews #NiftyIT #TechnologySector #ShareMarketUpdates
Disclaimer: Investment in securities market is subject to market risks. Read all related documents carefully before investing.
1186
294
shared an insight ⚡️ 7 hours ago
PI Industries Share Price Update: Stock Nears 52-Week Low
PIIND Share Price Update: Stock Nears 52-Week Low Following Weak Q2 FY27 Results and Export Challenges
Stock Market Overview
PI Industries Ltd (NSE: PIIND) closed at ₹1,597.40 on November 20, 2026, registering a decline of 2.00%. The stock traded close to its 52-week low of ₹1,595, reflecting continued selling pressure following disappointing second-quarter FY27 financial performance and persistent challenges in the export business.
Key Recent Developments
1. Q2 FY27 Financial Performance Under Pressure
PI Industries reported a subdued performance for the September quarter, with revenue declining approximately 9–10% year-on-year to nearly ₹1,702 crore. Net profit witnessed a sharper contraction of around 70%, falling to approximately ₹122 crore. .
2. Domestic Business Provides Some Support
Despite weakness in the export segment, the company's domestic agrochemical business, biologicals and health sciences divisions continued to demonstrate positive growth. These segments could provide support to the company's business performance amid challenging global market conditions.
3. Product Commercialisation Pipeline
Management highlighted plans to commercialise five products during FY27, indicating continued focus on expanding its product portfolio, strengthening innovation and improving long-term business prospects.
4. Export Business Remains a Key Concern
Soft demand in international markets, inventory-related challenges and lower export realisations remain important factors affecting the company's near-term growth outlook. A sustained recovery in global agrochemical demand will be crucial for improving revenue and profitability.
Stock Outlook
PI Industries shares remain under pressure following weak quarterly earnings and concerns over export-led business growth. Trading close to the 52-week low indicates cautious investor sentiment.
Investment in securities market is subject to market risks. Read all related documents carefully before investing.
1031
389
shared an insight ⚡️ 22 hours ago
NATCO Pharma Receives Seven USFDA Observations at Hyderabad
NATCOPHARM Pharma Receives Seven USFDA Observations at Hyderabad Manufacturing Unit
Key Highlights
!NATCO Pharma Limited has disclosed that it received seven observations from the US Food and Drug Administration (USFDA) following an inspection of its manufacturing facility located in Kothur, Hyderabad.
The regulatory inspection was carried out between 12 November and 20 November 2026. At the end of the inspection, the USFDA issued seven observations through Form 483.
Regulatory Details
The USFDA conducted an inspection of NATCO Pharma's Hyderabad manufacturing plant.
Seven observations were communicated to the company through Form 483.
A Form 483 is issued when USFDA inspectors identify conditions that, in their assessment, may indicate potential violations of regulatory requirements.
NATCO Pharma stated that it considers the observations to be procedural in nature.
The company expressed confidence in resolving all identified observations comprehensively within the prescribed timelines.
Company Statement
NATCO Pharma has indicated that it is committed to addressing the regulatory observations within the stipulated timeframe and strengthening its compliance standards.
Market Perspective
The development is an important regulatory update for NATCO Pharma. Investors may monitor the company's response, corrective measures and any subsequent updates from the USFDA to assess the potential business implications.
#NATCOPharma #USFDA #PharmaceuticalNews #CorporateUpdate #RegulatoryCompliance #Form483 #PharmaSector #StockMarketNews #IndianPharmaIndustry #BusinessNews
Disclaimer
market investments are subject to market risks.
What are the top stock recommendations by Anish Rai?
Anish Rai regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include INFY, PIIND and NATCOPHARM. Explore Anish Rai's complete list of posts and trade views on their StockGro profile.
How can I follow Anish Rai's latest investment insights?
You can follow Anish Rai's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Anish Rai's investment strategy?
Anish Rai follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Anish Rai been a SEBI-registered Research Analyst (RA)?
Anish Rai has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Anish Rai's past performance and stock picks?
You can check Anish Rai's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Anish Rai for stock market advice?
For stock market guidance from Anish Rai, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Anish Rai's track record in predicting market movements?
Anish Rai has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Anish Rai?
Anish Rai is a SEBI-registered Research Analyst with the SEBI Registration INH000026460. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.